GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » Research & Development

Context Therapeutics (FRA:6K9) Research & Development : €14.07 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Context Therapeutics's Research & Development for the three months ended in Mar. 2024 was €1.82 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €14.07 Mil.

Context Therapeutics Research & Development Historical Data

The historical data trend for Context Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics Research & Development Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
2.17 1.35 3.37 6.69 16.31

Context Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.24 3.20 4.20 4.86 1.82

Context Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Context Therapeutics  (FRA:6K9) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Context Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (FRA:6K9) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » Research & Development
Comparable Companies
NTRB AZTR KALA MYMD LSTA ICU AXLA EQ COCP MBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CNTX:USA 6K9:Germany
Address
2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Website
https://www.contexttherapeutics.com
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Context Therapeutics (FRA:6K9) Headlines

No Headlines